CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Taliglucerase alfa

Last Updated: August 15, 2014
Result type: Reports
Project Number: SR0390-000
Product Line: Reimbursement Review

Generic Name: Taliglucerase alfa

Brand Name: Elelyso

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: Gaucher disease

Indications: Gaucher disease

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 28, 2015

Recommendation Type: Do not list